Why Waiting for Second Line May Cost Patients Everything CNS progression changes lives — permanently.This clip tackles sequencing dilemmas, real-world attrition, and why delaying DB09 may deny patients their best chance at durable control.A sobering, practice-changing conversation. FacebookXRedditPinterestEmail You may also like Video Is DB09 Leading Towards A New First-Line Standard Of Care? – Drs. Krie, Mardones, & O’Dea 1 min read Video From CLEOPATRA to DESTINY-Breast09: A Decade of Change in Metastatic HER2+ Disease 1 min read Video DB09 Delivers 40-Month PFS: A First-Line Breakthrough 1 min read Video Why First-Line Choice Matters More Than Ever in HER2+ mBC 1 min read Video Managing T-DXd: Fatigue, Nausea, Hair Loss & Dose Reductions 1 min read Video ILD with T-DXd: Early detection. Proactive monitoring. The keys to T-DXd safety. 1 min read Recommended Videos Rethinking First-Line Metastatic HER2+ Therapy with T-DXd – Drs. Mouabbi, O’Shaughnessy & Rimawi 4 months ago Is HER2+ Metastatic Breast Cancer Curable? What Comes Next – Dr. Gregory Vidal & Dr. Nusayba Bagegni 4 months ago Rewriting Neoadjuvant & Adjuvant HER2+ Breast Cancer Strategy -Drs. Alison Conlin & Heather McArthur 4 months ago Datopotamab Deruxtecan vs Sacituzumab Govitecan Explained – Dr. Bill Gradishar & Dr. Tiffany Traina 4 months ago
Video Is DB09 Leading Towards A New First-Line Standard Of Care? – Drs. Krie, Mardones, & O’Dea 1 min read
Rethinking First-Line Metastatic HER2+ Therapy with T-DXd – Drs. Mouabbi, O’Shaughnessy & Rimawi 4 months ago
Is HER2+ Metastatic Breast Cancer Curable? What Comes Next – Dr. Gregory Vidal & Dr. Nusayba Bagegni 4 months ago
Rewriting Neoadjuvant & Adjuvant HER2+ Breast Cancer Strategy -Drs. Alison Conlin & Heather McArthur 4 months ago
Datopotamab Deruxtecan vs Sacituzumab Govitecan Explained – Dr. Bill Gradishar & Dr. Tiffany Traina 4 months ago